Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Chemical Linkers in Antibody-Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety.

Antibody-drug conjugates.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book summarizes the related research achievements in Antibody-drug conjugates (ADCs) and their cell metabolism kinetics. The book has three main parts. The first part describes the basic theory of ADCs, including the basic concept and structure of ADCs, and the relationship between the targets of ADCs and their specific functions. The second part mainly introduces the endocytosis and intracellular metabolism of ADCs, including the relationship between endocytosis and ADC activity, the endocytosis and intracellular transport of ADCs, the distribution and metabolism of ADC in vivo. Then it discusses the new formats and research technology of ADCs, including the application of miniaturized antibodies in ADC synthesis, novel carriers for ADC design, the technology and application of site-specific conjugation, and approaches for analyzing the drug: antibody ratio (DAR), the study of pharmacokinetics of ADCs. This book combines the basic theory with the research technology. It can be used as a reference book for students, teachers and researchers of biomedical field.

Biology—Technique. --- Experimental immunology. --- Pharmaceutical chemistry. --- Medicine—Research. --- Biology—Research. --- Cytology. --- Clinical biochemistry. --- Immunological Techniques. --- Pharmaceutics. --- Biomedical Research. --- Cell Biology. --- Medical Biochemistry. --- Medical biochemistry --- Pathobiochemistry --- Pathological biochemistry --- Biochemistry --- Pathology --- Cell biology --- Cellular biology --- Biology --- Cells --- Chemistry, Medical and pharmaceutical --- Chemistry, Pharmaceutical --- Drug chemistry --- Drugs --- Medical chemistry --- Medicinal chemistry --- Pharmacochemistry --- Chemistry --- Immunology, Experimental --- Biology, Experimental --- Immunology --- Immunoconjugates. --- Immunotherapy. --- Immunologic Techniques. --- Chemistry, Pharmaceutical. --- Chemistry, Pharmaceutic --- Pharmaceutic Chemistry --- Pharmaceutical Chemistry --- Medicinal Chemistry --- Chemistry, Medicinal --- Antibody Dissociation --- Immunologic Technic --- Immunologic Technics --- Immunologic Technique --- Immunological Technics --- Immunological Techniques --- Technic, Immunologic --- Technics, Immunologic --- Technique, Immunologic --- Techniques, Immunologic --- Antibody Dissociations --- Dissociation, Antibody --- Dissociations, Antibody --- Immunological Technic --- Immunological Technique --- Technic, Immunological --- Technics, Immunological --- Technique, Immunological --- Techniques, Immunological --- Allergy and Immunology --- Immunity --- Immunochemistry --- Immunotherapies --- Combined Antibody Therapeutics --- Immunity, Active --- Immunologic Techniques --- Antibody-Drug Conjugates --- Immunoconjugate --- Radioimmunoconjugate --- Antibody Drug Conjugate --- Antibody-Drug Conjugate --- Radioimmunoconjugates --- Antibody Drug Conjugates --- Conjugate, Antibody Drug --- Conjugate, Antibody-Drug --- Conjugates, Antibody-Drug --- Drug Conjugate, Antibody --- Molecular Targeted Therapy --- methods --- Antibody-drug conjugates. --- Antibody-toxin conjugates.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics provides the interested and informed reader with an overview of current approaches, strategies and considerations relating to the purification, analytics and characterization of therapeutic antibodies and related molecules. While there are obviously other books published in and around this subject area, they seem to be either older (c.a. year 2000 publication date) or are more limited in scope. The book will include an extensive bibliography of the published literature in the respective areas covered. It is not, however, intended to be a how-to methods book.

Antibody-drug conjugates. --- Immunoglobulins. --- Antibodies --- Immune globulins --- Immune serum globulin --- Blood proteins --- Globulins --- Plasma cells --- Antibody diversity --- Antigens --- Bacterial immunoglobulin-binding proteins --- Conjugates, Antibody-drug --- Drug-antibody conjugates --- Drug immunoconjugates --- Drug-immunoglobulin conjugates --- Immunoconjugates, Drug --- Immunoglobulin-drug conjugates --- Bioconjugates --- Drugs --- Immunopharmacology --- Dosage forms

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s.  The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies.  The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy.  ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics.  More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use.  This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.

Antibodies. --- Antibody-drug conjugates. --- Immunotoxins -- Therapeutic use. --- Antibody-drug conjugates --- Antibody-toxin conjugates --- Diseases --- Pharmaceutical Preparations --- Immunoconjugates --- Immunoglobulins --- Therapeutics --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Immunoproteins --- Chemicals and Drugs --- Blood Proteins --- Proteins --- Amino Acids, Peptides, and Proteins --- Immunotoxins --- Neoplasms --- Drug Therapy --- Antibodies --- Drug Combinations --- Medicine --- Health & Biological Sciences --- Oncology --- Antibody-toxin conjugates. --- Conjugates, Antibody-toxin --- Immunoglobulin-toxin conjugates --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Conjugates, Antibody-drug --- Drug-antibody conjugates --- Drug immunoconjugates --- Drug-immunoglobulin conjugates --- Immunoconjugates, Drug --- Immunoglobulin-drug conjugates --- Medicine. --- Cancer research. --- Biomedicine. --- Cancer Research. --- Biomedicine general. --- Immune globulins --- Immune serum globulin --- Blood proteins --- Globulins --- Plasma cells --- Antibody diversity --- Antigens --- Bacterial immunoglobulin-binding proteins --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Drugs --- Dosage forms --- Oncology. --- Monoclonal antibodies. --- Antibodies, Monoclonal --- Monoclonal immunoglobulins --- Molecular cloning --- Tumors --- Health Workforce --- Biomedicine, general.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed more than 25 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering has led to the generation of new classes of bispecific antibodies capable of circumventing many of these obstacles. Furthermore, new applications were established for bispecific antibodies, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy. In this book, the different means of generating bispecific antibodies are described, with an emphasis on recombinant formats, and information on the various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies, but also on emerging applications such as dual targeting strategies, i.e., the simultaneous inhibition of two targets (cytokines, receptors, etc.) are provided. This book is intended for a broad readership in the field of antibody engineering, mainly from the pharmaceutical and biotechnology sector, but also including academic researchers working in this field.

Antibodies, Bispecific. --- Antibody-drug conjugates. --- Antibody-toxin conjugates. --- Molecular biology. --- Immunoglobulins --- Antibodies --- Serum Globulins --- Immunoproteins --- Globulins --- Blood Proteins --- Proteins --- Amino Acids, Peptides, and Proteins --- Chemicals and Drugs --- Antibodies, Bispecific --- Biology --- Health & Biological Sciences --- Microbiology & Immunology --- Bispecific antibodies. --- Immunoglobulins. --- Immune globulins --- Immune serum globulin --- Heterospecific antibodies --- Medicine. --- Cancer research. --- Antibodies. --- Oncology. --- Biomedicine. --- Cancer Research. --- Blood proteins --- Plasma cells --- Antibody diversity --- Antigens --- Bacterial immunoglobulin-binding proteins --- Monoclonal antibodies. --- Oncology  . --- Tumors --- Antibodies, Monoclonal --- Monoclonal immunoglobulins --- Molecular cloning --- Cancer research